Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Insulin: Dosing Regimen and Adverse Effects01:16

Insulin: Dosing Regimen and Adverse Effects

1.1K
Insulin-replacement therapy usually includes both long-acting insulin (basal) and short-acting insulin (to cater to postprandial needs). In a diverse group of type 1 diabetes patients, the average daily insulin dose is typically 0.5-0.7 units/kg body weight. However, obese patients and pubertal adolescents may need more due to insulin resistance.
The basal dose constitutes about 40%-50% of the total daily dose, with the rest as premeal insulin. The mealtime insulin dose should mirror...
1.1K
Insulin Formulations: Types and Delivery01:27

Insulin Formulations: Types and Delivery

1.0K
Insulin preparations are categorized by their duration of action into short-acting and long-acting types. Two strategies are used to modify insulin's absorption and pharmacokinetic profile: slowing the absorption post-subcutaneous injection, or altering human insulin's amino acid sequence or protein structure. These changes retain the insulin's ability to bind to the insulin receptor, but alter its behavior in solution or after injection.
Short-acting insulins are divided into...
1.0K
One-Compartment Open Model for IV Bolus Administration: General Considerations01:19

One-Compartment Open Model for IV Bolus Administration: General Considerations

899
The one-compartment model is a pharmacokinetic tool that models the body as a single, uniform compartment, facilitating the understanding of drug distribution and elimination. This model is particularly beneficial for intravenous (IV) bolus administration, where the drug rapidly circulates throughout the body.
The drug's presence in the body is defined by an equation representing the difference between the rates of drug entry and exit. Key parameters—elimination rate constant,...
899
Insulin: Biosynthesis, Chemistry, and Preparation01:25

Insulin: Biosynthesis, Chemistry, and Preparation

1.8K
The endoplasmic reticulum (ER) of pancreatic β-cells synthesizes preproinsulin, which consists of a signal peptide, A and B chains, and a C-peptide. Preproinsulin is then cleaved and folded into proinsulin, which translocates to the Golgi apparatus for sorting and packaging into secretory granules. In these granules, enzymatic clipping generates insulin and C-peptide.
Damage or functional impairment of β-cells inhibits insulin production, leading to diabetes. Diabetes treatment...
1.8K
Diabetes: Management and Pharmacotherapy01:15

Diabetes: Management and Pharmacotherapy

1.4K
The therapy for diabetes aims to alleviate hyperglycemia-related symptoms, prevent acute metabolic decompensation, and reduce chronic end-organ complications. Glycemic control is evaluated through short-term (self-monitoring, continuous glucose monitoring) and long-term (A1c, fructosamine) metrics, enabling near real-time tracking of blood glucose levels and reflecting glycemic control over specific time frames.
Insulin remains the cornerstone of treatment for most patients with type 1 and many...
1.4K
Oral Hypoglycemic Agents: Glinides01:06

Oral Hypoglycemic Agents: Glinides

897
Repaglinide (Prandin) and Nateglinide (Starlix), known as glinides, are oral insulin secretagogues that stimulate insulin release from pancreatic β cells by closing the ATP-sensitive potassium channels (KATP channel). Repaglinide controls insulin release from pancreatic β cells by managing potassium efflux. It shares two binding sites with sulfonylureas and also has a unique site, indicating overlapping mechanisms of action. With a rapid onset and a 4-7 hour duration, it effectively...
897

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Corrigendum to "Clinical assessment and acceptance criteria for continuous glucose monitoring (CGM) system performance: A proposed guideline by the IFCC working group on CGM" [Clin. Chim. Acta 580 (2026) 120728].

Clinica chimica acta; international journal of clinical chemistry·2026
Same author

Glucose Monitoring and Control Testing in Patients with Type 1 or Type 2 diabetes.

Experimental and clinical endocrinology & diabetes : official journal, German Society of Endocrinology [and] German Diabetes Association·2026
Same author

The Relevance of Error Grid Analysis in ISO 15197.

Journal of diabetes science and technology·2026
Same author

Definition, Classification, Diagnostics and Differential Diagnostics of Diabetes Mellitus: Update 2025.

Experimental and clinical endocrinology & diabetes : official journal, German Society of Endocrinology [and] German Diabetes Association·2026
Same author

Integrating the Glycemia Risk Index Into Clinical Practice and Research: A Consensus Report.

Journal of diabetes science and technology·2026
Same author

Performance of a New Continuous Glucose Monitoring System in German Adults Living with Diabetes.

Diabetes therapy : research, treatment and education of diabetes and related disorders·2025

Related Experiment Video

Updated: Mar 19, 2026

Improving IV Insulin Administration in a Community Hospital
12:08

Improving IV Insulin Administration in a Community Hospital

Published on: June 11, 2012

19.5K

Boluses in Insulin Therapy.

Ralph Ziegler1, Guido Freckmann2, Lutz Heinemann3

  • 11 Diabetes Clinic for Children and Adolescents, Muenster, Germany.

Journal of Diabetes Science and Technology
|June 9, 2016
PubMed
Summary

Optimizing insulin boluses is crucial for multiple dose insulin therapy (MDI). This commentary discusses factors influencing bolus effectiveness and highlights technological advancements like bolus advisors for improved diabetes management.

Keywords:
bolusbolus advisorcontinuous subcutaneous insulin infusioninsulin therapyprandial insulin

More Related Videos

Study of In Vivo Glucose Metabolism in High-fat Diet-fed Mice Using Oral Glucose Tolerance Test OGTT and Insulin Tolerance Test ITT
08:13

Study of In Vivo Glucose Metabolism in High-fat Diet-fed Mice Using Oral Glucose Tolerance Test OGTT and Insulin Tolerance Test ITT

Published on: January 7, 2018

72.4K
Intra-Omental Islet Transplantation Using h-Omental Matrix Islet filliNG hOMING
07:36

Intra-Omental Islet Transplantation Using h-Omental Matrix Islet filliNG hOMING

Published on: March 14, 2019

7.5K

Related Experiment Videos

Last Updated: Mar 19, 2026

Improving IV Insulin Administration in a Community Hospital
12:08

Improving IV Insulin Administration in a Community Hospital

Published on: June 11, 2012

19.5K
Study of In Vivo Glucose Metabolism in High-fat Diet-fed Mice Using Oral Glucose Tolerance Test OGTT and Insulin Tolerance Test ITT
08:13

Study of In Vivo Glucose Metabolism in High-fat Diet-fed Mice Using Oral Glucose Tolerance Test OGTT and Insulin Tolerance Test ITT

Published on: January 7, 2018

72.4K
Intra-Omental Islet Transplantation Using h-Omental Matrix Islet filliNG hOMING
07:36

Intra-Omental Islet Transplantation Using h-Omental Matrix Islet filliNG hOMING

Published on: March 14, 2019

7.5K

Area of Science:

  • Endocrinology
  • Metabolic Diseases
  • Pharmacology

Background:

  • Multiple dose insulin therapy (MDI) requires careful bolus insulin administration alongside basal insulin.
  • Optimal bolus adjustment depends on meal composition, carbohydrate content, correction factors, and timing.

Purpose of the Study:

  • To address key factors influencing bolus insulin effectiveness in MDI therapy.
  • To highlight current technological opportunities and challenges in bolus administration.
  • To emphasize the need for further research to refine insulin therapy.

Main Methods:

  • This is a commentary, not an experimental study.
  • Discussion of influencing factors in bolus insulin therapy.
  • Review of current technologies and future research directions.

Main Results:

  • Bolus insulin optimization is complex, involving multiple patient-specific and meal-related factors.
  • Technological aids like bolus advisors can assist, but challenges remain.
  • Continuous subcutaneous insulin infusion (CSII) offers advanced delivery options.

Conclusions:

  • Effective bolus insulin administration is essential for successful MDI therapy.
  • Further research is needed to overcome technical challenges and improve bolus advisor algorithms.
  • Optimizing boluses, supported by technology, can enhance diabetes management outcomes.